Drugs / Pamiparib
Trials 34 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04614909 | Jan 2021 → Jul 2023 | adult glioblastoma | Nader Sanai | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05526924 | Mar 2023 → Jan 2028 expected | head and neck squamous cell carcinoma, pharynx cancer | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT05573373 | Dec 2022 → Nov 2024 | non-small cell lung carcinoma | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
| Phase 1 | NCT05038839 | Feb 2022 → May 2026 | refractory malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03991494 | May → Oct 2019 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03994211 | May → Oct 2019 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03749187 | Apr 2019 → Jun 2026 overdue | glioblastoma, grade II glioma, grade III glioma | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03150810 | Jun 2017 → May 2023 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02660034 | Feb 2016 → Sep 2020 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02361723 | Jul 2014 → Sep 2019 | — | BeiGene | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT05494580 | Sep 2022 → Jun 2024 | fallopian tube carcinosarcoma, ovarian carcinoma, primary peritoneal carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 1/2 | NCT03914742 | Feb 2020 → Oct 2023 | glioblastoma, grade II glioma, grade III glioma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1/2 | NCT03150862 | Jul 2017 → Mar 2021 | brain cancer | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT03333915 | Dec 2016 → Aug 2020 | ovarian cancer, triple-negative breast carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06387056 | Apr 2024 → Apr 2026 overdue | metastatic prostate carcinoma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06145308 | Aug 2023 → Jul 2028 expected | salivary gland carcinoma | Peking Union Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT05669768 | Jan 2023 → Jul 2024 | ovarian cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05652283 | Nov 2022 → May 2024 overdue | ovarian cancer | Bai-Rong Xia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05489926 | Aug 2022 → Jun 2024 | malignant epithelial tumor of ovary | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05044871 | Jul 2022 → Feb 2025 | ovarian cancer | Tongji Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05483543 | Jun 2022 → Dec 2024 | small cell lung carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05327621 | May 2022 → Mar 2025 | castration-resistant prostate carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04796454 | May 2022 → Jul 2026 | — | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04985721 | Feb 2022 → Aug 2025 | cancer | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 2 | NCT05376722 | Feb 2022 → Sep 2023 | — | Hongqian Guo | Unknown | No outcome recorded |
| Phase 2 | NCT04603365 | Oct 2021 → May 2023 | clear cell papillary renal cell carcinoma, collecting duct carcinoma, hereditary leiomyomatosis and renal cell cancer, hereditary papillary renal cell carcinoma +1 | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05406999 | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT03933761 | Jul 2019 → Aug 2021 | carcinosarcoma, ovarian cancer | Australia New Zealand Gynaecological Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT03712930 | Feb 2019 → Aug 2020 | castration-resistant prostate carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 2 | NCT03427814 | Jul 2018 → Jun 2020 | gastric cancer | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT03575065 | Jun 2018 → Oct 2020 | Her2-receptor negative breast cancer | BeiGene | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT03519230 | May 2018 → Dec 2025 overdue | ovarian cancer | BeiGene | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 36 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pamiparib | “Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer” NCT05573373 ↗30“Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.” NCT05406999 ↗ “60mg pamiparib (BGB-290) PO BID” NCT03749187 ↗ “pamiparib 60 mg PO bid” NCT06145308 ↗ |
| Known as | BGB-290 | “A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics...” NCT03994211 ↗ |
| Action | Inhibit | “pamiparib, an oral PARP 1/2 inhibitor” PMID 31378459 ↗ Aug 2019 |
| Modality | Small molecule | “Pamiparib is a small molecule inhibitor selectivity for both PARP1 and PARP2.” NCT05494580 ↗ |
| Route | Oral | “20, 40, or 60 mg oral pamiparib twice daily” PMID 31378459 ↗ Aug 2019 |
| Target | PARP1 | “excellent selectivity for both PARP1 and PARP2” PMID 32652442 ↗ Jul 2020 |
| Target | PARP2 | “excellent selectivity for both PARP1 and PARP2” PMID 32652442 ↗ Jul 2020 |